Nitish Kumar lays foundation stone for Rs 264-crore Tibbi College Hospital in Patna
The ambitious project, estimated to cost around Rs 264 crore, will be developed over 10 acres of land behind the B.Sc. Nursing School and the State Pharmacy Institute.
State Health Minister Mangal Pandey and Bihar Assembly Speaker Nand Kishore Yadav were also present at the ceremony.
Ahead of the event, Health Department Secretary Manoj Kumar Singh and Bihar Medical Services and Infrastructure Corporation Limited (BMSICL) Managing Director Dharmendra Kumar visited the site to assess preparedness and issued key directives.
The hospital will be equipped with a 200-bed Unani hospital across five storeys, an academic block for 150 students, an air-conditioned auditorium with 500 seating capacity, a residential complex for the principal, superintendent, doctors, and staff, and hostel facilities for candidates.
The construction work will be completed by 2027, according to engineers from BMSICL.
Senior NMCH officials, including Principal Prof. Usha Kumari, Superintendent Prof. Rishm Prasad, and Deputy Superintendent Saroj Kumar, were present during the inauguration.
Currently, the Tibbi College Hospital operates from Kadamkuan. Its principal, Prof. Mahfoozur Rahman, expressed optimism that the new infrastructure will significantly enhance academic standards and healthcare delivery.
On Friday, Prime Minister Narendra Modi inaugurated and laid the foundation stone for various projects worth Rs 48,500 crore during the Karakat rally.
The projects included a thermal power plant in Navinagar in Aurangabad, Varanasi-Gaya-Kolkata six-lane expressway, Patna-Gaya-Dobhi four-lane national highway and Bihta airport and many others.
PM Modi also spotlighted the growing focus on Bihar's Makhana industry after the Centre allotted it a GI tag and how lakhs of farmers are benefitting from it.
He had inaugurated the newly constructed terminal building of Jay Prakash Narayan International Airport in Patna on Thursday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Contraceptive injections for 15 dists
Patna: In order to improve family planning in the state, the govt decided to provide MPA-Subcutaneous, a form of injection, which is effective in contraception for three months, in 15 districts and a subdermal implant facility in 13 districts, said health minister Mangal Pandey. As of now, these health facilities are being provided on a pilot basis in select districts.
Time of India
2 hours ago
- Time of India
Body of Kodagu man being brought back from Guyana
Madikeri: Mortal remains of a resident of Kodagu, who died in Guyana, will be brought back to India, the Non-Resident Indian Forum said on Wednesday. The state govt will extend financial assistance to bring back the body of PB Girish Babu Pale, who is a native of Madenadu village in Madikeri taluk, it stated. Girish was working as a staff nurse in the Sheriff General Hospital in Guyana, South America, for about two years. On July 3, he was admitted to the hospital where he was working due to illness and was undergoing treatment. However, he died of a heart attack on July 14. Following the incident, the family was in constant touch with the hospital and the Indian Embassy to bring the mortal remains to India. The embassy informed that the family of the deceased would have to pay about Rs 12 lakhs to bring the mortal remains to India. Janaki, wife of Girish, appealed to the Non-Resident Indian Forum for assistance from the govt, stating that the family was financially backward. Accordingly, the forum requested chief minister Siddaramaiah to consider the request. Janaki also met the CM and sought his intervention. In response, the state govt sanctioned Rs 3.6 lakh while the remaining amount is being borne by the Sheriff General Hospital where Girish worked, the Forum stated on Wednesday. In addition, the alumni of Basavanahalli Morarji Desai Residential School, where Girish studied, approached Virajpet MLA AS Ponnanna and requested him to provide financial assistance. The Indian Embassy in Guyana and the resident commissioner in New Delhi are coordinating the bringing of the body to India.
Economic Times
2 hours ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
